John Freeman

Senior Director, Development Team Leader - Interventional Oncology at Johnson & Johnson @Johnson & Johnson

Manchester, GB
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Jul 2023 — Present

Senior Director, Development Team Leader - Interventional Oncology at Johnson & Johnson @Johnson & Johnson

View department →

Manchester, GB

Evolving from the Lung Cancer Initiative at J&J, the Interventional Oncology R&D unit is focused on developing novel drug and energy therapies delivered directly into tumors through minimally invasive procedures. Our primary focus will remain in lung cancer given our expertise and significant patient need. Additionally, we will work on clinically adjacent cancer types with similar biology for greater patient impact.

EDUCATION

1988 — 1991

University of Leeds

Bachelor of Science (BSc), Pharmacology

1991 — 1994

The University of Manchester

Doctor of Philosophy (PhD), Neurophysiology

SKILLS

MelanomaMedical DiagnosticsProject PlanningClinical DevelopmentIch-GcpClinical MonitoringTeam LeadershipBiotechnologyDrug DevelopmentCancerGcpHealthcareRegulatory SubmissionsPharmaceutical IndustryStrategyClinical ResearchProject ManagementLung CancerStrategic PlanningLine ManagementOncologyProtocolClinical TrialsCROLife SciencesLifesciencesCross-Functional Team LeadershipBreast CancerTherapeutic AreasCtmsOvarian Cancer

ABOUT JOHN FREEMAN

I’m a UK-based pharmaceutical executive with over 25 years of experience in oncology drug development, spanning global leadership roles in both pharma and CRO environments. Currently, I am a Senior Director and Development Team Leader at Johnson & Johnson, where I lead the development of novel therapies delivered directly into tumors through minimally invasive techniques.My career has been shaped by a strong track record of designing and delivering complex, innovative oncology clinical programs across all phases of development. At AstraZeneca, I led the global clinical development team for Tagrisso (osimertinib), achieving regulatory approvals in the US, EU, and Japan in under three years from first-in-human. At IQVIA, I expanded the oncology biotech portfolio by over 200%, overseeing programs for 30+ clients worldwide.With deep expertise in lung, head & neck, breast, and other solid tumors, I bring strategic insight, scientific rigor, and operational execution to every program I lead. I’m passionate about developing impactful cancer therapies and building high-performing, cross-functional teams to bring them to patients faster.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

John Freeman — Senior Director, Development Team Leader - Interventional Oncology at Johnson & Johnson at Johnson & Johnson in Manchester, GB | Unifers